Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TTYP01 in Adolescents and Children with Autism Spectrum Disorders
NCT06757504Phase 2Recruiting
- Start
- Jan 2025
- Primary completion
- Feb 2026
- Modality
- Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of FAB122 in Autism Spectrum Disorder (ASD) (3 arms). Primary endpoints: Aberrant Behavioral Checklist - Social Withdrawal at Week 12, Treatment-Emergent Adverse Events and 1 more. Started Jan 2025; status: recruiting.
02
Drugs
FAB122
03
Conditions
Autism Spectrum Disorder (ASD)
Beyond the preview
Go deeper on NCT06757504.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06757504.